Stem Cell Therapy for Diabetes and Related Conditions Market

The global Stem Cell Therapy for Diabetes and Related Conditions Market was valued at USD 510.0 million in 2025 and is estimated at USD 559.8 million in 2026. Revenue is projected to reach USD 1,179.7 million by 2034, representing a 9.8% CAGR during 2026–2034.

The commercial boundary covers development and preparation of stem-cell-derived pancreatic islet therapies, associated clinical manufacturing and licensing, and investigational cell-based protocols for diabetes complications. Experimental programmes do not have US marketing authorization. FDA-approved Lantidra uses deceased-donor islets, not stem-cell-derived beta cells, and its finished-product sales are excluded. For stem-cell treatment scope, iDF estimated 589 million adults living with diabetes in 2024 and projected 853 million by 2050.

The International Diabetes Federation reported 589 million adults with diabetes worldwide in 2024, with 9.1 million people affected by type 1 diabetes. Severe hypoglycemia and ineffective glucose self-regulation motivate research into insulin-secreting grafts. Most development activity targets selected high-risk patients, not the full diabetes population, limiting near-term clinical revenue. For diabetes demand, the 2025 IDF Atlas counted 9.1 million people with type 1 diabetes across age groups.

Vertex reported in June 2025 that ten of twelve patients treated with investigational zimislecel no longer needed insulin after one year of follow-up. The study involved full-dose stem-derived islets and immunosuppression, with Phase 3 evaluation continuing in 2026. Those results help direct investment toward standardized cell manufacturing rather than ordinary insulin distribution. For clinical evidence, vertex reported that 10 of 12 participants treated with zimislecel were insulin independent after one year in its June 2025 update.

Sana advanced the preclinical SC451 hypoimmune iPSC-derived programme in August 2026, while Orizuru supplied an iPSC islet sheet for a Japanese first-in-human trial in April 2025. Aspect and Novo Nordisk restructured their cell-therapy partnership in January 2026. Each programme could add process, licensing or investigational supply income before any approved stem-derived medicine reaches routine care. For pipeline development, vertex reported FDA clearance for the VX-017 clinical trial application in its August 2026 investor disclosure.

Source: IDF; Vertex 2025; Sana; Orizuru.

The study covers diabetes-directed stem-cell replacement and related investigational manufacturing, clinic-service and licensing activity, excluding insulin sales and non-stem-cell donor islet product revenues.

Unmet type 1 diabetes demand funds investigational cell replacement

The IDF Atlas counts 9.1 million people living with type 1 diabetes, but the first stem-derived islet studies focus on patients with serious hypoglycemia despite intensive insulin care. Vertex enrolled that high-risk population in its zimislecel programme, where 10 of 12 full-dose recipients became insulin independent at one year. This narrow initial eligibility limits procedure volume while supporting higher spending on cell differentiation, transplant follow-up and GMP release tests. For type 1 patient eligibility, orizuru Therapeutics supplied OZTx-410 for its first Japanese clinical implantation in April 2025.

Immune protection shapes product design and contract costs

Vertex zimislecel involves systemic immunosuppression, while Sana is developing SC451 using gene-edited cells designed to avoid broad immunosuppression. iTolerance combines stem-derived islet cells with an immune-protective microgel. Separate approaches require distinct potency assays, host-response studies and manufacturing documentation, making process development a sizable component of contracted activity before conventional reimbursement begins. For transplant immunology, sernova published 2025 clinical interim data involving donor-derived islets while separately developing an Evotec iPSC collaboration. For transplant immunology, evotec described scalable GMP-grade iPSC-derived islet-like cluster manufacturing in its preclinical partnership with Sernova.

Industry partnerships broaden scalable differentiation technology

Aspect Biosystems and Novo Nordisk entered a new collaboration phase on 20 January 2026, transferring selected technologies and capabilities into the Canadian platform. Sernova and Evotec continue development of iPSC-derived islet clusters for the Cell Pouch system. These initiatives can reduce reliance on deceased donors, but companies must demonstrate robust batch consistency before broad clinical access becomes possible. For islet cell scale-up, iTolerance describes iTOL-102 as a preclinical project involving stem-cell-derived pancreatic cells and localized immune protection. For islet cell scale-up, fDA approved Lantidra in June 2023 for deceased-donor islets rather than stem-cell-derived replacement cells.

Clinical and regulatory uncertainty restrains marketed revenue

FDA approved donor-islet Lantidra in 2023, but it is not a stem-derived medicine; the agency has not authorized the experimental iPSC-derived diabetes programmes for general marketing. Japan began an investigator-led iPSC islet sheet trial in 2025, and Vertex remained in Phase 1/2/3 testing during 2026. Clinical setbacks or manufacturing comparability issues could delay investment recovery and commercial launches. For development-stage risks, fDA warns consumers about unapproved stem-cell products marketed for many diseases. For development-stage risks, a September 2024 Cell report described one Chinese patient achieving insulin independence following autologous chemically induced iPSC-derived islet transplantation.

Diabetic complications create research opportunities but not equal treatment readiness

The IDF estimated 589 million adults with diabetes in 2024, the majority with type 2 disease. Mesenchymal-cell research addresses wound healing and kidney or nerve injury, but it is clinically distinct from functional pancreatic beta-cell replacement. Development costs are tied to individual trial protocols; broad diabetes prevalence cannot be translated directly into stem-cell therapy use without comparative efficacy data. For diabetic complication research, kyoto University Hospital identified its April 2025 OZTx-410 implantation as a safety-focused investigator-initiated trial. For diabetic complication research, juvenile Diabetes Cure Alliance identified 15 companies developing stem-derived beta-cell supply in February 2026.

Sources: International Diabetes Federation, Vertex Pharmaceuticals, FDA, Aspect Biosystems and Sana Biotechnology.

Stem-derived insulin secretion outcomes guide phase-three investment

Vertex published June 2025 results showing 10 of 12 full-dose zimislecel participants had achieved insulin independence at month twelve, with all twelve meeting HbA1c and time-in-range targets. Vertex later reported a cleared IND for VX-017 in August 2026, adding another investigation route. Evidence of sustained endogenous insulin secretion attracts manufacturing and translational research funding, but no stem-derived islet product was yet generally approved. For pivotal trial decisions, sana and Mayo Clinic announced a 2026 collaboration involving standardization of SC451 clinical development.

Gene editing and immune evasion become parallel strategies

CRISPR Therapeutics described CTX213 as an edited iPSC-derived precursor-cell programme in its August 2026 earnings update. Sana reported continued manufacturing work on its SC451 hypoimmune iPSC product during the same month. Because immune rejection can necessitate lifelong medication, companies are evaluating alternative protective mechanisms alongside cell potency and differentiation yield. For immune-evasion technologies, brazil and Mexico are in the IDF South and Central America region, where the Atlas reports 35 million adults with diabetes. For immune-evasion technologies, the IDF Atlas estimates 25 million adults with diabetes in Africa and 85 million in its Middle East and North Africa region.

Japan and China generate distinct early clinical signals

Kyoto University Hospital implanted an Orizuru OZTx-410 iPSC-derived islet sheet in a patient during 2025, with safety follow-up described in its April notice. A 2024 Cell paper from China reported sustained insulin independence in one autologous chemically induced iPSC-islet recipient. Both are early investigations involving small patient numbers, making long-term safety and reproducibility essential before reimbursement can scale. For Asia-Pacific islet trials, german company Evotec and Canadian firm Sernova cooperate on experimental iPSC-derived islets and an implantable cell-support device.

Cell-device combinations address graft survival

Sernova reported clinical results from donor islet grafts in its Cell Pouch during 2025, while Evotec is developing an iPSC-derived alternative for that platform. iTolerance separately describes the iTOL-102 stem-islet protective microgel programme. The platform distinction matters: favorable donor-islet data do not constitute evidence that a newer stem-derived combination has already demonstrated equivalent clinical outcomes. For combination therapy research, japanese clinical researchers use an iPSC-derived islet cell sheet made by Orizuru Therapeutics, rather than an approved insulin replacement medicine.

Manufacturing capability transfers across partner networks

The January 2026 Aspect-Novo Nordisk agreement positioned the Vancouver company to lead advanced cellular therapy development and absorb selected technologies from Novo Nordisk. Sana announced a Mayo Clinic collaboration in May 2026 focused on SC451 development and clinical protocols. Additional controlled manufacturing capacity can expand investigational supply as these collaborations move toward human testing, conditional on meeting quality and regulator requirements. For cross-border islet manufacturing, the 2025 Vertex investor release documented UK MHRA Innovation Passport and EMA PRIME designations for zimislecel.

Stem-derived cell products such as Vertex zimislecel and Orizuru OZTx-410 are being investigated to restore glucose-responsive insulin secretion in selected type 1 patients. Vertex uses fully differentiated stem-derived cell transplantation; Orizuru uses an iPSC-derived cell sheet; CRISPR Therapeutics and Sana emphasize engineered islets. Separate clinical programmes examine mesenchymal-cell effects on tissue repair, but those results cannot be transferred to beta-cell replacement claims. For cell replacement landscape, iDF estimated 589 million adults living with diabetes in 2024 and projected 853 million by 2050.

Type 1 diabetes involves autoimmune loss of endogenous insulin-producing beta cells, which is why stem-derived cell replacement programmes prioritize glucose-responsive beta-cell function. The 2025 Vertex update documented C-peptide production and a reduction in exogenous insulin in its trial population. Replicating those results at manufacturing scale requires controlled differentiation, assessment of residual undifferentiated cells and long-term graft monitoring. For beta-cell function, the 2025 IDF Atlas counted 9.1 million people with type 1 diabetes across age groups. For beta-cell function, vertex reported that 10 of 12 participants treated with zimislecel were insulin independent after one year in its June 2025 update.

FDA approval of Lantidra establishes that deceased-donor human islet cell therapy can be regulated, but the donor source is categorically different from iPSC or embryonic stem-cell-derived products. Sernova similarly reports clinical Cell Pouch experience using donor islets while its Evotec partnership is developing a future stem-derived substitute. Combining those revenue streams would misrepresent commercial stem-cell therapy adoption. For donor and stem-cell distinction, vertex reported FDA clearance for the VX-017 clinical trial application in its August 2026 investor disclosure.

A Chinese investigator-led report described a single autologous induced-islet recipient with insulin independence after transplantation, while Kyoto documented initial OZTx-410 graft surgery in April 2025. Patient-level outcomes justify additional research but cannot establish population-wide treatment effectiveness. For international clinical evidence, sana stated in August 2026 that SC451 had not yet begun its Phase 1/2 clinical study and remained in manufacturing preparation. For international clinical evidence, cRISPR Therapeutics described CTX213 as a gene-edited iPSC-derived islet precursor programme in its August 2026 financial update.

Stem-cell diabetes service revenue is allocated between products developed as stand-alone cell interventions and combinations requiring separate devices or immune modification. Sernova and Evotec document cell-pouch combination engineering, while Vertex is testing the fully differentiated zimislecel product under systemic immune suppression. Each project is assigned once to the design being developed. For Type research, aspect Biosystems and Novo Nordisk expanded their cellular-medicine partnership on 20 January 2026.

Cell therapy may be delivered within multidisciplinary diabetes care, so classification follows the developed product or device combination. FDA-approved donor-islet medicine is excluded, irrespective of whether it is administered with immunosuppressive treatment. For Type follow-up, fDA approved Lantidra in June 2023 for deceased-donor islets rather than stem-cell-derived replacement cells.

Cell-replacement trials and complication-focused studies differ in biology, patient selection and measured outcomes. Vertex concentrates on severe type 1 diabetes, while mesenchymal approaches in foot, kidney and nerve complications remain separate investigations. No conventional insulin, dialysis or wound-care products are counted within the stem-cell revenue boundary. For Application research, fDA warns consumers about unapproved stem-cell products marketed for many diseases.

The facilities conducting clinical islet graft implantation differ from diabetes follow-up clinics and laboratory research groups. Kyoto University Hospital reported the first OZTx-410 implant in 2025, while academic institutions also contributed Chinese autologous islet studies. Sponsors purchase defined medical, manufacturing and research services across these environments. For End User research, the IDF Atlas estimates 25 million adults with diabetes in Africa and 85 million in its Middle East and North Africa region.

Commercial status depends on whether a stem-derived product is in enrolled human trials, being prepared for studies, or authorized for general patient sales. Vertex and Orizuru are in clinical development; Sana and CRISPR Therapeutics describe earlier programmes. No authorized commercial stem-derived pancreatic replacement drug was identified in 2025. For Therapy Stage research, vertex reported that 10 of 12 participants treated with zimislecel were insulin independent after one year in its June 2025 update.

North American stem-derived islet trials and Canadian cell-technology partnerships drive development service activity; European partners invest in manufacturing, while Japan and China have reported experimental implantation cases. Latin America and the Middle East & Africa have large diabetes burdens but limited documented stem-derived cell commercialization.

Access depends on clinical-trial eligibility and the infrastructure needed for investigational islet cell transplantation. Vertex enrolled people with severe hypoglycemic events, whereas Sana and CRISPR Therapeutics were preparing other cell-engineered programmes in 2026. FDA authorization of deceased-donor Lantidra does not confer approval on stem-derived products; reimbursement follows each product separately. For transplant access, vertex reported FDA clearance for the VX-017 clinical trial application in its August 2026 investor disclosure. For transplant access, sana stated in August 2026 that SC451 had not yet begun its Phase 1/2 clinical study and remained in manufacturing preparation.

The FDA 2023 Lantidra approval covered deceased-donor pancreatic islets in selected adults unable to control recurrent severe hypoglycemia. It is clinically relevant as a regulatory comparator but does not convert experimental pluripotent-cell products into marketed therapies. Stem-derived programmes must demonstrate differentiation purity, graft survival and product-specific safety before payers consider routine benefit design. For FDA therapy regulation, cRISPR Therapeutics described CTX213 as a gene-edited iPSC-derived islet precursor programme in its August 2026 financial update. For FDA therapy regulation, aspect Biosystems and Novo Nordisk expanded their cellular-medicine partnership on 20 January 2026.

Hospitals must coordinate imaging, immunosuppression assessment, procedure handling and long-term clinical monitoring for experimental islet grafts. Kyoto University Hospital reported its first OZTx-410 implantation in 2025, and Vertex evaluated patients with severe hypoglycemia in its multi-stage study. Those eligibility constraints keep initial treatment volumes far below overall diabetes prevalence. For hospital procedure economics, orizuru Therapeutics supplied OZTx-410 for its first Japanese clinical implantation in April 2025. For hospital procedure economics, sernova published 2025 clinical interim data involving donor-derived islets while separately developing an Evotec iPSC collaboration.

Sana and Mayo Clinic agreed in May 2026 to support development protocols for SC451. Clinical partnerships can increase manufacturing and specialist service expenditures even before therapeutic sales begin. Sernova and Evotec likewise separate clinical donor-cell experience from a future iPSC-derived product, making reimbursement forecasts conditional on the cell source actually used. For clinical-stage collaboration, evotec described scalable GMP-grade iPSC-derived islet-like cluster manufacturing in its preclinical partnership with Sernova. For clinical-stage collaboration, iTolerance describes iTOL-102 as a preclinical project involving stem-cell-derived pancreatic cells and localized immune protection.

Source: FDA; Vertex; Kyoto University Hospital.

The US FDA has approved donor-derived islet cell therapy but no stem-derived beta-cell medicine for general diabetes treatment in the cited programme set. Vertex’s zimislecel remained investigational in 2026, and separate sponsors were developing genetically engineered alternatives. Regulatory oversight covers cell provenance, manufacturing consistency, graft safety and long-term follow-up. For regulatory development, fDA approved Lantidra in June 2023 for deceased-donor islets rather than stem-cell-derived replacement cells. For regulatory development, fDA warns consumers about unapproved stem-cell products marketed for many diseases.

Vertex received regulatory designations in the US, EU and UK for zimislecel, but Fast Track, PRIME and Innovation Passport programmes support interactions rather than authorize sales. Its August 2026 disclosure separately discussed FDA-cleared plans for VX-017. Each cell product needs its own development dossier; authorization of donor islet Lantidra does not apply automatically to a stem-derived line. For authorization status, a September 2024 Cell report described one Chinese patient achieving insulin independence following autologous chemically induced iPSC-derived islet transplantation.

Sana SC451 is an O-negative hypoimmune-modified iPSC-derived islet candidate, whereas the published UP421 trial used donor-derived islets. CRISPR Therapeutics described CTX213 as engineered iPSC islet precursor cells in its August 2026 release. This product-source distinction changes how potency, genomic safety and rejection risks must be assessed during clinical qualification. For manufacturing regulation, kyoto University Hospital identified its April 2025 OZTx-410 implantation as a safety-focused investigator-initiated trial. For manufacturing regulation, juvenile Diabetes Cure Alliance identified 15 companies developing stem-derived beta-cell supply in February 2026.

Kyoto University Hospital tracked one OZTx-410 clinical recipient following an April 2025 announcement; a Chinese investigator group also reported one autologous islet transplant case in 2024. These examples are feasibility observations rather than broad efficacy demonstrations. Expansion depends on comparative studies and traceable manufacture across batches, including safe removal of undifferentiated cells. For regulatory trial follow-up, sana and Mayo Clinic announced a 2026 collaboration involving standardization of SC451 clinical development. For regulatory trial follow-up, brazil and Mexico are in the IDF South and Central America region, where the Atlas reports 35 million adults with diabetes.

A dozen verified firms participate in stem-derived diabetes cell therapy development or its enabling platforms. Vertex leads advanced investigational graft evidence, while Sana and CRISPR Therapeutics pursue gene-edited approaches. Evotec supplies differentiated beta cells to Sernova, and Aspect Biosystems has an extended partnership with Novo Nordisk. No named firm should be presented as selling an FDA-approved stem-derived islet medicine in 2025. For competitive cellular medicines, the IDF Atlas estimates 25 million adults with diabetes in Africa and 85 million in its Middle East and North Africa region.

The Juvenile Diabetes Cure Alliance documented 15 for-profit entities developing stem-derived beta-cell supplies in February 2026, with only five cell lines already in human trials. Companies therefore compete at different regulatory stages, and clinical progress cannot be inferred from the number of technology announcements. Programmatic funding, partnerships and cell production services remain important until approved finished treatments generate repeatable product revenue. For cell development company activity, the 2025 IDF Atlas counted 9.1 million people with type 1 diabetes across age groups.

• Vertex Pharmaceuticals Incorporated
• CRISPR Therapeutics AG
• Sana Biotechnology, Inc.
• Aspect Biosystems Ltd.
• Novo Nordisk A/S
• Sernova Biotherapeutics Inc.
• Evotec SE
• Orizuru Therapeutics, Inc.
• NewcelX Ltd.
• iTolerance, Inc.
• Humacyte, Inc.
• Pluristyx, Inc.

Stem-cell-related diabetes therapy development and service revenue is projected at USD 1,179.7 million in 2034, up from USD 559.8 million in 2026, with 9.8% CAGR for the period.

Vertex has reported continued zimislecel clinical development with long-term patient monitoring, while the IDF estimates 9.1 million people living with type 1 diabetes. Only patients meeting rigorous eligibility criteria are realistic early recipients of experimental grafts. Continued research payments and cell-manufacturing projects may increase revenue before reimbursement of any new approved cell medicine. For islet cell market growth, orizuru Therapeutics supplied OZTx-410 for its first Japanese clinical implantation in April 2025. For islet cell market growth, sernova published 2025 clinical interim data involving donor-derived islets while separately developing an Evotec iPSC collaboration.

Edited islet projects could reduce post-transplant immune rejection, but Sana SC451 and CRISPR Therapeutics CTX213 had not demonstrated general clinical approval in August 2026. The cost structure involves master cell banks, differentiation validation, genomic assays and long-term safety testing. Delays in clinical entry would slow contract demand even if research investment continues. For gene-edited stem therapies, evotec described scalable GMP-grade iPSC-derived islet-like cluster manufacturing in its preclinical partnership with Sernova. For gene-edited stem therapies, iTolerance describes iTOL-102 as a preclinical project involving stem-cell-derived pancreatic cells and localized immune protection.

Orizuru clinical implantation at Kyoto University and the 2024 Chinese autologous transplant report demonstrate contrasting allogeneic and patient-derived approaches. Geographic uptake is limited by specialist infrastructure, hospital approval and local regulatory review. Latin American and African diabetes prevalence may expand research interest, but patient counts cannot be treated as addressable cell-therapy volume. For international trial services, fDA approved Lantidra in June 2023 for deceased-donor islets rather than stem-cell-derived replacement cells. For international trial services, fDA warns consumers about unapproved stem-cell products marketed for many diseases.

The 2034 estimate depends on clinical trial progression, technical-transfer agreements, graft survival and future market authorizations. Aspect and Novo Nordisk expanded manufacturing collaboration in 2026, while Sernova and Evotec work on implantable iPSC clusters. In a scenario without successful authorizations, value would remain concentrated in limited clinical research and specialist service contracts rather than high-volume medicine sales. For future diabetes therapy adoption, a September 2024 Cell report described one Chinese patient achieving insulin independence following autologous chemically induced iPSC-derived islet transplantation. For future diabetes therapy adoption, kyoto University Hospital identified its April 2025 OZTx-410 implantation as a safety-focused investigator-initiated trial.

The study addresses stem-cell-related therapeutic development for diabetes, including clinical-stage cell replacement, investigational complications and manufacturing or licensing activity across five regions.